Eosinophilic asthma is an asthma phenotype characterized by eosinophilic airway inflammation. It is recognized as a specific subtype within asthma phenotyping and often associated with type-2 inflammatory pathways. This phenotype can require targeted biologic therapy in severe disease.
Drug Hunter's monthly molecule selections from July through December 2025 feature innovative small molecule candidates targeting pain, epilepsy, cancer, infectious diseases, and metabolic disorders, including non-opioid pain agents and precision therapies for rare conditions.
The FDA approved 46 novel drugs in 2025, down from 50 in 2024. Small molecules accounted for 31 approvals (67%), with oncology leading at nine approvals. Large molecules contributed 15 approvals (33%), spanning ADCs, bispecifics, and subcutaneous delivery innovations.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07343661 |
Beyond EOsinophils: proteoMICS to Identify Potential Biomarker of Organ Damage and Response to MEPOLIZUMAB in EGPA |
ENROLLING_BY_INVITATION | PHASE4 |
| NCT07323654 |
A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma |
RECRUITING | PHASE2 |
| NCT07250594 |
A Multi-dose Study on the Safety and Efficacy of Self-administered Intranasal AD17002 Treatment for Eosinophilic Asthma |
NOT_YET_RECRUITING | PHASE2 |
| NCT06911775 |
Eosinophil Subpopulations in Eosinophilic-associated Diseases |
NOT_YET_RECRUITING | |
| NCT06750289 |
Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment |
RECRUITING | PHASE3 |
| NCT06388889 |
Phase III Long-Term Extension Study With Dexpramipexole |
TERMINATED | PHASE3 |
| NCT05985694 |
AD17002 Treating Poorly Controlled, Moderate to Severe Eosinophilic Asthma |
COMPLETED | PHASE1/PHASE2 |
| NCT05813288 |
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3) |
TERMINATED | PHASE3 |
| NCT05763121 |
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma. |
TERMINATED | PHASE3 |
| NCT05748600 |
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma |
ACTIVE_NOT_RECRUITING | PHASE3 |
